Salute e Benessere

Oxurion geeft een update met betrekking tot de strategie voor investering in…

Leuven, BELGIË, 9 oktober 2025, 18u00 – Oxurion NV (Euronext Brussel: OXUR) kondigt vandaag aan dat de afronding van de nieuwe financiering gericht op investeringen in digitale activa (Bitcoin en Ethereum), waarvan de closing oorspronkelijk gepland was op 25 september 2025, nog in voorbereiding is. De administratieve en compliance-gerelateerde…
Actusnews Wire
09/10/2025

Coloplast interim CEO Lars Rasmussen will step down from the Board at the…

Announcement no. 09/2025 Inside information Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting Coloplast interim CEO Lars Rasmussen has today informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, 2025. “On behalf of the Board, I want to thank Lars for his unwavering dedication to Coloplast. Through his commitment to the company for...
Nasdaq GlobeNewswire
09/10/2025

Idorsia launches an offering of registered shares – to fund the company to…

Ad hoc announcement pursuant to Art. 53 LR Idorsia launches an offering of approximately 15 million newly issued and treasury shares through an accelerated bookbuilding process, to extend operating cash runway into 2028The net proceeds of this offering will fund Idorsia’s disciplined, phased investment in accelerating QUVIVIQ’s commercial trajectory toward commercial profitability in 2026 and advancing a de-risked, science-driven pipelineAllschwil, Switzerland – October 9, 2025...
Nasdaq GlobeNewswire
09/10/2025

OUTCOMES4ME NAMED TO TIME'S LIST OF THE BEST INVENTIONS OF 2025

"We are honored that TIME recognizes Outcomes4Me for 'demystifying cancer care' and the important work we are doing to improve health outcomes for all people living with cancer," Dr. Said continued. "We are honored that TIME recognizes Outcomes4Me for 'demystifying cancer care' and the important work we are doing to improve health outcomes for all people living with cancer," Dr. Said continued. To compile this year's Best Inventions list, which features 300 extraordinary…
PR Newswire
09/10/2025

Endoscopy Procedures Market to Reach $617.8 billion, Globally, by 2034 at 5.5%…

Endoscopy can help diagnose conditions such as ulcers, tumors, infections, and inflammation, and it is also used for performing biopsies, removing polyps, or treating bleeding. It offers benefits such as reduced recovery time, less pain, and lower risk compared to traditional surgery, as endoscopy typically involves small incisions or natural body openings. Endoscopic procedures are usually performed on an outpatient basis and are guided by real-time imaging to ensure precision and safety. ...
PR Newswire
09/10/2025

Lifespan-Backed Algen Biotechnologies Partners with AstraZeneca to Advance AI…

Harry Robb, Principal at Lifespan Vision Ventures, said "We are thrilled to see Algen Biotechnologies achieve this important milestone. The team has built a truly differentiated platform that integrates CRISPR-based functional screening with advanced AI analytics to uncover disease-relevant biology at scale. This collaboration with AstraZeneca underscores the strength of Algen's technology and its potential to transform drug discovery." Harry Robb, Principal at Lifespan Vision…
PR Newswire
09/10/2025

Softgel Capsules Market Size to Reach US$ 14.1 Billion by 2032, Growing at 6.3%…

Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/softgels-capsules-market Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/softgels-capsules-market Browse in-depth TOC on "Softgel Capsules Market" 54 – Tables 42 – Figures 180 – Pages Rising Demand for Personalized...
PR Newswire
09/10/2025

ECMO Machine Market worth US$0.86 billion by 2030 with 5.8% CAGR |…

Browse in-depth TOC on "ECMO Machine Market" Browse in-depth TOC on "ECMO Machine Market" 250 - Tables 50 - Figures 350 - Pages By product,the market of ECMO machines is divided into components and ECMO machines. In 2024, the components segment held the largest share of the global ECMO machines market. The component segment benefits from rapid innovation in oxygenator design, centrifugal pumps, and digital controllers. For example, polymethyl pentene (PMP) hollow-fiber...
PR Newswire
09/10/2025

Feminine Intimate Care Market to Reach $14 billion, Globally, by 2034 at 6.1%…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A291929 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A291929 Prime determinants of growth Growing disposable incomes, knowledge of personal cleanliness, and the desire for organic and natural products are the main factors propelling the market for feminine intimate care. Women's adoption of improved hygienic habits and the move toward...
PR Newswire
09/10/2025

Wearable Medical Devices Market Poised for USD 499.2 Billion by 2035, Growing at…

Why This Market Matters to CXOs Why This Market Matters to CXOs The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.vantagemarketresearch.com/wearable-medical-devices-market-2927/request-sample Free Sample Includes: Technological & Industry Momentum Strategic Opportunities for Business Leaders Expert Insights "Wearable medical devices are becoming the backbone of preventive and personalized...
PR Newswire
09/10/2025

Medical Aesthetics Market to Surge from US$ 18.48 Billion in 2024 to US$ 55.99…

Recent advancements, particularly in minimally invasive devices and AI-assisted treatment planning, are expanding the customer base beyond traditional dermatology practices to medical spas, beauty centers, and outpatient clinics. Recent advancements, particularly inminimally invasive devices and AI-assisted treatment planning,are expanding the customer base beyond traditional dermatology practices tomedical spas, beauty centers, and outpatient clinics. Download PDF Brochure:...
PR Newswire
09/10/2025

Cardiovascular Drugs Market to 2030: APAC Leads Growth and Telehealth Helps…

The Asia-Pacific region leads the cardiovascular drug market, driven by reforms and expanding healthcare infrastructure, which also boost opportunities for local companies and increase competition for international players. Japan's faster approval process supports the adoption of advanced therapies, including newer anticoagulants and metabolic treatments. TheAsia-Pacificregion leads the cardiovascular drug market, driven by reforms and expanding healthcare infrastructure, which also boost...
PR Newswire
09/10/2025

Hagar hf.: – Information on the publication of Q2 2025/26 results

Hagar hf. will publish its financial results for Q2 2025/26, covering the period 1 June to 31 August 2025, after market close on Thursday, 16 October 2025.A presentation meeting for investors and market participants will be held at Nauthóll, Nauthólsvegur 106, Reykjavík, on Friday, 17 October 2025, at 8:30 a.m.At the meeting, Finnur Oddsson, CEO, and Guðrún Eva Gunnarsdóttir, CFO, will present the company’s operations and financial performance and answer questions.The meeting will also...
Nasdaq GlobeNewswire
09/10/2025

Kimberly-Clark Launches Enhanced Global Partnerships to Advance Essential Care…

This announcement is a direct result of the Kimberly-Clark Foundation's recent sharpening of its strategic focus: to advance essential care for women and girls on their journeys through puberty and motherhood. The foundation will fund this three-year, $28.7 million commitment, which focuses on menstrual care and maternal & infant care. This announcement is a direct result of theKimberly-Clark Foundation 's recent sharpening of its strategic focus: to advance essential care for women and...
PR Newswire
09/10/2025

LuX-Valve Plus Approved for Hong Kong-Macao Medicine and Equipment Connect

LuX-Valve Plus has successfully obtained this approval for commercial clinical application in mainland of GBA by leveraging its extensive successful clinical application experience, outstanding clinical performance, and unique and advanced product design in major countries/regions worldwide, including Asia-Pacific, North America, Europe, South America, and Middle East. Through this access pathway, LuX-Valve Plus is expected to initially meet the urgent and substantial treatment needs of patients…
PR Newswire
09/10/2025

Field Medical First-in-Human 6-Month Data Selected for Late-Breaking Clinical…

Field Medical will be featured across three sessions, including first-in-human six-month outcomes from its FieldForce™ Ablation System, the first focal contact-force PFA platform designed for VT, a pre-recorded live VT case and translational preclinical research. Field Medical will be featured across three sessions, including first-in-human six-month outcomes from its FieldForce™ Ablation System, the first focal contact-force PFA platform designed for VT, a pre-recorded live VT case and...
PR Newswire
09/10/2025

Consortium consisting of Nordic Capital and Permira receives final regulatory…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, 9 October, 2025– With reference to the announcements of 26 August 2025 (no. 24/2025 and no. 25/2025) and the announcement of 29 September 2025 (no. 27/2025) concerning the all-cash voluntary recommended public takeover offer to acquire all of the issued and outstanding...
Nasdaq GlobeNewswire
09/10/2025

Simple Life raises $35M Series B to scale its AI health coach for lasting weight…

"I'm hyped to back Simple through my fund HartBeat Ventures. Simple is truly changing the game in health, and HBV wants to be front row for that," said Kevin Hart, founder of Hartbeat Ventures. "I'm hyped to back Simple through my fund HartBeat Ventures. Simple is truly changing the game in health, and HBV wants to be front row for that," saidKevin Hart, founder of Hartbeat Ventures. Solving a$340 billionmarket gap Weight management is one of the largest consumer health...
PR Newswire
09/10/2025

Adcendo ApS Announces FDA Fast Track Designation Granted to ADCE-D01 for the…

ADCE-D01 is currently being evaluated in the ADCElerate1 clinical trial, a first-in-human Phase I/II multicenter, open-label, dose escalation and expansion study evaluating ADCE-D01 as a monotherapy in patients with metastatic and/or unresectable STS. The primary objective of the study is to evaluate the safety and tolerability of ADCE-D01. The secondary objectives are to characterize the pharmacokinetics and to evaluate the preliminary efficacy of ADCE-D01. The study is recruiting in the US…
PR Newswire
09/10/2025

Tilray Brands Reports Strong First Quarter Fiscal 2026 Results, Highlighting…

Operational Efficiencies and Focus on Profitability Drove Net Income of $1.5 Million, Adjusted EBITDA Increased 9% to $10 Million and Net Cash Used in Operations Improved by $34 Million Year-Over-YearCanadian Adult-Use Cannabis Gross Revenue Increased 12%, Maintaining the #1 Position in Revenue and Expanding Market Share; International Cannabis Revenue Grew 10% Year-Over-YearBalance Sheet Strengthened to $265 Million in Cash; Net Debt Reduced to $4 Million...
Nasdaq GlobeNewswire
09/10/2025

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new…

/Ridgefield, Connecticut, U.S.Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function. 1 Approval is based on results from two clinical trials, which showed reduction in Forced Vital Capacity decline with JASCAYD versus placebo in adults with idiopathic pulmonary fibrosis (IPF). 2,3 Nerandomilast is a new treatment option for adult patients with IPF with a well-tolerated safety profile. 2,3Boehringer Ingelheim’s JASCAYD ®...
Nasdaq GlobeNewswire
09/10/2025

Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting…

"With the validation of PrecisionSphere's capabilities and our proven track record of executing several key strategic partnerships each year, we are ready to expand patient access to advanced LAI treatments through new global strategic collaborations," said Dr. Fabrice Egros, President – Corporate Development, Lupin. "Our extensive in-house and successful alliance management capabilities will serve as a strategic advantage, as partners strive to deliver innovative LAI solutions to…
PR Newswire
09/10/2025

Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21…

Acquisition adds potential first- and best-in-class asset, enhancing Novo Nordisk’s portfolio for treatment of MASH, one of the most prevalent obesity related comorbiditiesAkero Therapeutics’s FGF21 analogue efruxifermin is the only treatment to show significant fibrosis regression in phase 2 in patients with compensated cirrhosis (F4)Novo Nordisk to acquire Akero Therapeutics for 54 USD per share (4.7 billion USD) in cash at closing with a contingent value right (CVR) of 6 USD per share...
Nasdaq GlobeNewswire
09/10/2025

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Zymeworks Inc.(Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer.In this role, Dr. Schayowitz will report directly to Zymeworks’ Chair & Chief Executive Officer, Kenneth Galbraith, and work...
Nasdaq GlobeNewswire
09/10/2025
Altri  Comunicati